National Health (Pharmaceutical Benefits) Regulations (Amendment)

Overview

The Regulations under the National Health Act 1953-1956, enacted in 1957, address the need to update the pharmaceutical benefits provided under the National Health Scheme. These regulations were introduced to amend the National Health (Pharmaceutical Benefits) Regulations, ensuring that the list of subsidised medications and treatments remained relevant and effective in meeting the health needs of the population. The amendments were made by the Governor-General in and over the Commonwealth of Australia, acting on the advice of the Federal Executive Council. The overarching policy objective was to expand the range of treatments and medications that could be subsidised under the national health scheme, thereby improving access to essential healthcare for Australians. The regulations came into effect on the first of October, 1957, and included the addition of new pharmaceutical items to both the First and Second Schedules of the National Health (Pharmaceutical Benefits) Regulations. This expansion was intended to ensure that the scheme covered a broader array of medical conditions and treatments, reflecting advances in medical science and public health needs. These changes aimed to enhance the overall effectiveness and reach of the National Health Scheme, ensuring that Australians had access to necessary medications and treatments that were previously not covered.

Scope and Application

The Statutory Rules 1957, No. 52, made under the National Health Act 1953-1956, amend the National Health (Pharmaceutical Benefits) Regulations to extend the list of pharmaceutical benefits provided under the Act. These Regulations, which came into operation on the first day of October 1957, modify the First and Second Schedules of the existing regulations to include additional pharmaceutical substances and indications for treatment. Specifically, the First Schedule now includes Bimuth Glycollylarsanilate, Mecamylamine, and Syntocinon, while the Second Schedule adds Calcium Benzoyl Para-Aminosalicylate for tuberculosis, specific conditions such as Still’s disease in children under the age of 16 years, ulcerative colitis, and Henoch’s purpura, and adjusts the indications for Cyanocobalamin and introduces Nystatin for proven monilia infections and Penicillin with Streptomycin for certain types of endocarditis. These amendments apply to the whole of the Commonwealth of Australia, affecting all persons who are eligible for the Pharmaceutical Benefits Scheme. The Regulations do not specify any exclusions or exemptions, thereby extending the scope of benefits to include the newly listed substances and conditions.

Key Provisions

The main operative sections of these Regulations (C1957L00052) primarily concern amendments to the National Health (Pharmaceutical Benefits) Regulations. Specifically, they introduce new pharmaceutical items to be covered under the National Health Act 1953-1956. For instance, Section 2(a) adds "Bismuth Glycollylarsanilate" after item 13, "Mecamylamine" after item 80, and "Syntocinon" after item 159 to the First Schedule. The Second Schedule is amended in Section 3 to include "Calcium Benzoyl Para-Aminosalicylate (B-Pas)" after item 2 and to add specific conditions under the "Disease or Purpose" column, such as "Still’s disease in children under the age of 16 years" and "Ulcerative colitis proven by sigmoidoscopy and radiological report" under item 12. Other notable amendments include the replacement of item 13 with new items "Cyanocobalamin (strengths other than 1,000 microgramme strength)" and "Cyanocobalamin (1,000 microgramme strength)" with respective conditions, and the addition of "Nystatin" after item 26 and "Penicillin with Streptomycin" after item 32. The Regulations impose several obligations on parties involved, primarily ensuring that the newly listed pharmaceutical items are available for coverage under the National Health scheme. This means that healthcare providers and patients can now seek reimbursement or subsidised access to these medications through the scheme. The amendments also require health professionals to comply with the specified conditions for prescribing certain drugs, such as the need for a sigmoidoscopy and radiological report for "Ulcerative colitis" and specific indications for the use of "Nystatin" and "Penicillin with Streptomycin". While the Regulations themselves do not explicitly outline specific offences, penalties, or civil/criminal consequences for breaches, any failure to comply with the National Health Act 1953-1956 could lead to enforcement actions by the relevant authorities. These could include fines, sanctions, or other legal actions as prescribed under the overarching Act. The specific penalties would be determined based on the nature and severity of the breach, in line with the provisions of the National Health Act.